Emerging biotech funding
Funding-ready from concept to clinical impact
Breakthrough science deserves a clear path to the clinic. ICON helps emerging biotechs translate discovery into investor‑ready development plans, sharpen Target Product Profiles (TPPs), optimise pitch materials, and connect with the right investors, including through relationships with venture funds where ICON is a Limited Partner (LP).
What today’s investors expect
Securing capital is competitive and capital costs remain elevated. The rising cost of capital is shaping operations, while cost management is a leading barrier to innovation. At the same time, trial complexity remains a top challenge to progress.
-
52%
are using large pharma partnerships as a current funding method* -
39%
rely on venture capital investment*
* 2025 Biotech global sector survey
These trends underscore the need for credible clinical plans, clear investor narratives, and strategic partnerships.
How ICON accelerates funding readiness
We bring deep expertise across trial design, regulatory strategy and commercialisation to help you demonstrate value to investors and move faster towards your next milestone.
VC connectivity
ICON is a Limited Partner in several leading venture funds and so we understand what investors are looking for. It is vital to address the company’s long-term strategy, to demonstrate the long-term value and clinical benefit, which will ultimately dictate the return on investment.
How can ICON’s Venture Capital Alliances team help?
Seed → Series A:
You have strong pre-clinical data. ICON shapes your clinical strategy, builds a robust TPP, stress‑tests your endpoints and feasibility and refines your investor deck — we ensure that your message resonates with targeted early‑stage funds.
Pre‑IND to first‑in‑human:
You need a credible route to safety and early efficacy signals. ICON aligns your enabling studies, regulatory plan and early clinical design to maximise value inflection and shorten time to data. This is often a decisive milestone for funding.
Crossover to pivotal‑readiness:
You’re now at the scaling stage. ICON sharpens your global trial strategy, execution plan and real‑world evidence approach to support later‑stage investors and potential strategic partners.
Management excellence:
Trial complexity is the leading challenge facing biotechs. Investors reward credible management teams that proactively handle complexity, whilst simultaneously maintaining operational discipline. ICON fills the capability gaps in your management teams, to deliver the operational rigour and cross‑functional leadership investors expect.
FAQs
When should we engage ICON?
- As early as pre‑IND. Aligning plans to investor expectations and regulatory pathways early reduces risk and accelerates time to value.
What expertise can ICON bring to our investor materials?
- Cross‑functional depth in trial design, regulatory strategy and commercialisation ensures your plan, TPP and investor deck anticipate the diligence questions that matter.
What does “LP relationships” actually mean for a biotech seeking funding?
- “LP relationships” refers to ICON’s role as a Limited Partner in select venture funds, as well as its broader strategic relationships across the venture capital ecosystem. These relationships give ICON enhanced insight into evolving investor priorities, funding environments and early‑stage development expectations. We communicate these insights to our biotech customers, who then better understand how their programs may be evaluated by potential investors.
Optimising biotech funding whitepaper series
In this two-part whitepaper series on biotech funding, we firstly share insights on how biotechs can secure funding in a highly competitive market, and then shed light on the opportunities available to utilise these funds more effectively and efficiently.
Next steps – contact our Venture Capital Alliances team
We can help turn your scientific innovations into a funding‑ready plan.
Dedicated biotech division
Explore ICON Biotech services (8,000+ biotech‑dedicated professionals)